Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight (NASDAQ: RXST) reported Q1 2026 revenue of $30.9 million, down 18.5% year‑over‑year, with 27,472 LAL units and 20 LDDs sold, expanding the installed base to 1,154 LDD units. Gross margin was 76.1%. Net loss was $15.9 million (−$0.38/share). Cash and short‑term investments totaled $217.9 million. 2026 guidance reiterated: revenue $120–$135 million, gross margin 70–72%, and operating expenses at the high end of the prior $150–$160 million range.
RxSight (NASDAQ:RXST) will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026 at 3:00 p.m. PT. Management will take part in a fireside chat. A live and archived webcast will be available on the company’s investor relations website.
RxSight (NASDAQ: RXST) will report first-quarter 2026 financial results on May 6, 2026 after market close.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with dial-in numbers and a listen-only webcast on the company investor relations site; an archived recording will be posted after the call.
RxSight (NASDAQ: RXST) announced it has surpassed 300,000 Light Adjustable Lens (LAL) implants since launch and will feature 35 scientific presentations at ASCRS 2026.
Company highlights include published outcomes showing high refractive accuracy and a new surgeon-focused outreach program to expand patient access.
RxSight (NASDAQ: RXST) will present at the 25th Annual Needham Virtual Healthcare Conference. Management will participate in a fireside chat on April 16, 2026 at 8:00 a.m. PT. A live and archived webcast will be available on the company investor relations website.
RxSight (NASDAQ: RXST) reported 2025 results: full-year revenue of $134.5 million (down 4%), gross profit of $103.0 million (76.6% margin), and a net loss of $38.9 million (‑$0.95 per share).
LAL unit sales rose 12% to 109,615 units; LDD system sales fell 48% with 163 units. Cash and short-term investments totaled $228.1 million. 2026 guidance: revenue $120.0–$135.0 million, gross margin 70%–72%, operating expenses $150.0–$160.0 million.
RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and take questions.
Dial-in numbers, conference code 3406720, a live listen-only webcast and an archived recording will be available on the company’s investor relations website.
RxSight (Nasdaq: RXST) reported preliminary unaudited results for Q4 and full-year 2025 and named a new CFO effective Jan 11, 2026. Preliminary Q4 2025 revenue is expected to be approximately $32.6M, driven by sales of 28,611 Light Adjustable Lenses (LAL, +10% vs Q3 2025) and 25 Light Delivery Devices (LDD), bringing the installed base to 1,134 LDDs as of Dec 31, 2025. Preliminary FY2025 revenue is expected to be approximately $134.5M (vs prior guidance $125–$130M), with total LAL sales of 109,615 (+12% vs 2024) and 163 LDDs sold in 2025. Cash and short-term investments are expected to be $228.1M. Audited 2025 results and 2026 guidance will be released with Q4 earnings in February. Mark Wilterding is appointed CFO effective Jan 11, 2026.
RxSight (NASDAQ:RXST) announced that its management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT / 6:45 p.m. ET.
Investors and interested parties can access a live and archived webcast of the presentation at https://investors.rxsight.com/. No financial results or guidance were included in the announcement.
RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.
The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.